Wellington Management Group LLP Acquires 103,592 Shares of Artivion, Inc. $AORT

Wellington Management Group LLP increased its holdings in Artivion, Inc. (NYSE:AORT) by 9.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,260,279 shares of the company’s stock after buying an additional 103,592 shares during the period. Wellington Management Group LLP’s holdings in Artivion were worth $28,318,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion in the third quarter worth $27,000. Rockefeller Capital Management L.P. increased its holdings in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares during the period. Larson Financial Group LLC raised its position in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Artivion during the 4th quarter worth approximately $79,000. 86.37% of the stock is currently owned by institutional investors.

Artivion Price Performance

Shares of NYSE:AORT opened at $25.59 on Friday. Artivion, Inc. has a one year low of $19.16 and a one year high of $48.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -365.52 and a beta of 1.25. The firm has a 50 day simple moving average of $26.09 and a 200 day simple moving average of $29.21.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Research analysts predict that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artivion news, SVP Andrew Green sold 1,493 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.02, for a total value of $38,847.86. Following the completion of the transaction, the senior vice president owned 51,640 shares of the company’s stock, valued at $1,343,672.80. This represents a 2.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO James Mackin sold 70,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares of the company’s stock, valued at $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 122,981 shares of company stock worth $3,181,531 in the last 90 days. Insiders own 6.30% of the company’s stock.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $44.83.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.